Osi is an oral 3rd-gen ET that selectively inhibits ET sensitivity and EGFR T790M resistance (present in almost 60% of patients) and has been approved for the treatment of patients with metastatic T790M-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.